BioLineRx (NASDAQ: BLRX) director details extensive stock option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
BioLineRx Ltd. director Molcho Avraham filed an initial ownership report showing a portfolio of employee stock options to acquire Ordinary Shares. The filing lists multiple fully vested grants made between July 2016 and July 2024 under the 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.920 per share and expirations between 2026 and 2034. One large grant covers 2,055,000 underlying shares at an exercise price of $0.052 per share, expiring in 2034, of which 856,200 options were vested on the October 1, 2024 grant date and the remaining 1,198,800 options vest in seven equal quarterly installments, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Molcho Avraham
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 49,800 shares (Direct)
Footnotes (1)
- Options granted under the 2003 Amended and Restated Share Incentive Plan. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.
Key Figures
Largest option block: 2,055,000 underlying shares at $0.052
2022 option grant: 1,080,000 underlying shares at $0.085
2023 option grant: 360,000 underlying shares at $0.081
+5 more
8 metrics
Largest option block
2,055,000 underlying shares at $0.052
Employee stock option expiring August 14, 2034
2022 option grant
1,080,000 underlying shares at $0.085
Employee stock option expiring July 3, 2032
2023 option grant
360,000 underlying shares at $0.081
Employee stock option expiring July 3, 2033
2024 option grant
360,000 underlying shares at $0.085
Employee stock option expiring July 3, 2032
2019 option grant
199,800 underlying shares at $0.356
Employee stock option expiring July 2, 2029
Earliest option grant
49,800 underlying shares at $0.837
Employee stock option expiring July 5, 2026
Immediate vest portion (2025 grant)
856,200 options
Vested on October 1, 2024 appointment date
Unvested portion (2025 grant)
1,198,800 options
To vest in 7 equal quarterly installments
Key Terms
Employee Stock Option (Right to Buy), underlying security, 2003 Amended and Restated Share Incentive Plan, vested, +2 more
6 terms
Employee Stock Option (Right to Buy) financial
"security_title: "Employee Stock Option (Right to Buy)""
underlying security financial
""underlying_security_title": "Ordinary Shares""
vested financial
""This option grant is fully vested as of this date.""
Section 102 of the Israeli Tax Ordinance financial
""To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance""
trustee financial
""securities issued to an employee... must be registered in the name of a trustee""
A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.
FAQ
What does BioLineRx (BLRX) director Molcho Avraham report in this Form 3?
Molcho Avraham reports existing holdings of employee stock options to buy BioLineRx Ordinary Shares. These options were granted under the company’s 2003 Amended and Restated Share Incentive Plan, with various exercise prices and expiration dates, and represent his current derivative equity position.
Are Molcho Avraham’s BioLineRx stock options already vested?
Several grants are fully vested, including options granted between July 2016 and July 2024. For the October 1, 2024 grant, 856,200 options vested immediately, while 1,198,800 options vest in seven equal quarterly installments, subject to continued service.
What are the exercise prices on Molcho Avraham’s BioLineRx stock options?
The reported employee stock options have exercise prices ranging from $0.052 to $0.920 per Ordinary Share. Each grant has a specific strike price and expiration date, reflecting awards made over multiple years under the company’s share incentive plan.
When do Molcho Avraham’s BioLineRx stock options expire?
The option grants expire on dates between July 5, 2026 and August 14, 2034, depending on the original grant. Earlier grants from 2016–2018 expire in 2026–2028, while more recent low‑priced awards extend into the early 2030s if not exercised.
Under which plan were Molcho Avraham’s BioLineRx options granted?
All reported options were granted under BioLineRx’s 2003 Amended and Restated Share Incentive Plan. This plan governs the terms, vesting schedules, and tax-related arrangements for employee equity awards, including the use of a trustee structure for certain Israeli tax benefits.